Hutchmed (China) announced that it will receive a milestone payment of 10 million USD from its partner Takeda, due to the recommendation for public healthcare coverage for FRUZAQLA® (furmonertinib) in Spain. FRUZAQLA® is expected to be approved in the EU in June 2024 for the treatment of metastatic colorectal cancer, making it the first innovative oral targeted therapy of its kind approved in Europe in over a decade.The inclusion in the healthcare system is an important step in improving patient accessibility in Europe and reflects Hutchmed's and Takeda's shared commitment to addressing the needs of metastatic colorectal cancer patients. The approval of FRUZAQLA® is mainly based on the results of the FRESCO-2 international multicenter phase III study, the data...Show More

Hutchmed (China) announced that it will receive a milestone payment of 10 million USD from its partner Takeda, due to the recommendation for public healthcare coverage for FRUZAQLA® (furmonertinib) in Spain. FRUZAQLA® is expected to be approved in the EU in June 2024 for the treatment of metastatic colorectal cancer, making it the first innovative oral targeted therapy of its kind approved in Europe in over a decade.The inclusion in the healthcare system is an important step in improving patient accessibility in Europe and reflects Hutchmed's and Takeda's shared commitment to addressing the needs of metastatic colorectal cancer patients. The approval of FRUZAQLA® is mainly based on the results of the FRESCO-2 international multicenter phase III study, the data of which has been published in The Lancet. Currently, FRUZAQLA® has been approved in several countries including the USA, EU, Swiss Franc, Canada, Japan, and the United Kingdom.Colorectal cancer is the second leading cause of cancer-related deaths in Europe, and FRUZAQLA® provides new treatment options as a selective VEGFR inhibitor. Hutchmed will continue to collaborate with Takeda to advance the development and commercialization of FRUZAQLA® globally.